Patents by Inventor Andrew Dunford

Andrew Dunford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PANELS AND METHODS FOR TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20240117440
    Abstract: The invention provides a molecular classifier and a targeted sequencing assay for use in characterization and treatment of diffuse large B-cell lymphoma.
    Type: Application
    Filed: September 15, 2023
    Publication date: April 11, 2024
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Bjoern CHAPUY, Donald STEWART, Tim WOOD, Margaret SHIPP, Gad GETZ, Mark MURAKAMI, Lee LAWTON, Andrew DUNFORD, Kirsty WIENAND
  • COMPOSITIONS AND METHODS FOR CHARACTERIZING LYMPHOMA AND RELATED CONDITIONS
    Publication number: 20240052428
    Abstract: The invention provides compositions and methods useful in characterizing and/or treating classical Hodgkin's Lymphoma and/or primary mediastinal B-cell lymphoma (PMBL). In embodiments, the characterization is carried out using a biological sample comprising circulating tumor DNA (ctDNA) from a subject.
    Type: Application
    Filed: September 15, 2023
    Publication date: February 15, 2024
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Margaret SHIPP, Gad GETZ, Bjoern CHAPUY, Kirsty WIENAND, Donald STEWART, Andrew DUNFORD, Mark MURAKAMI, Lee LAWTON
  • THERAPEUTIC TREATMENT OF SELECT DIFFUSE LARGE B CELL LYMPHOMAS EXHIBITING DISTINCT PATHOGENIC MECHANISMS AND OUTCOMES
    Publication number: 20190292602
    Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of DLBCL. In particular, the instant disclosure provides a DLBCL classifier that has identified at least five distinct classes of DLBCL cancer, each of which possesses distinct pathogenic mechanisms and outcomes. The instant classifier identifies preferred therapeutic options (including combination therapies) for each such class of DLBCL cancer.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 26, 2019
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION
    Inventors: Bjoern Chapuy, Margaret Shipp, Chip Stewart, Andrew Dunford, Gad Getz